KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2017 - 2025)

Alnylam Pharmaceuticals' Capital Expenditures history spans 17 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 96.13% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $10.9 million, down 68.19%, while the annual FY2025 figure was $10.9 million, 68.19% down from the prior year.
  • Capital Expenditures reached $1.3 million in Q4 2025 per ALNY's latest filing, up from -$13.7 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $33.5 million in Q4 2024 to a low of -$45.2 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $6.5 million, with a median of $14.9 million recorded in 2023.
  • The largest YoY upside for Capital Expenditures was 1763.53% in 2025 against a maximum downside of 4155.14% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $21.9 million in 2021, then plummeted by 306.57% to -$45.2 million in 2022, then grew by 4.68% to -$43.1 million in 2023, then soared by 177.81% to $33.5 million in 2024, then plummeted by 96.13% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Capital Expenditures are $1.3 million (Q4 2025), -$13.7 million (Q3 2025), and $19.6 million (Q2 2025).